FDA gives thumbs-up
to Balversa
The U.S. FDA has granted approval of Balversa (erdafitinib) to Belgium-based Janssen Pharmaceutica, for the treatment of advanced or metastatic bladder cancer. This drug is the first ever approved target-specific medication targeting susceptible FGFR genetic mutations, and for cancer that has progressed during or following prior platinum-containing chemotherapy. FDA granted Balversa the Accelerated Approval to make drugs available for serious conditions and to fulfil unmet needs.
Gilead and Novo
Nordisk to target NASH together
Gilead Sciences and Novo Nordisk A/S have announced to join hands to fight Non-Alcoholic Steatohepat...
